A lead researcher in the Nordic Brain Network focused on the reverse translation of lifestyle intervention trials. Anna bridges the clinical and preclinical worlds, identifying early fluid biomarkers and molecular mechanisms of prevention to validate Fingerprint’s targets in vivo.